Login / Signup

Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo-controlled crossover laboratory study.

Ismene L PetrakisTracy NolenNathan VandergriftShawn HirschJohn H KrystalMichael De VivoJeff SabadosEmily PisaniJenelle NewcombThomas R Kosten
Published in: The American journal on addictions (2024)
This is the first study to provide scientific support for BXCL501's potential to treat PTSD and comorbid AUD.
Keyphrases
  • alcohol use disorder
  • placebo controlled
  • double blind
  • posttraumatic stress disorder
  • radiation therapy
  • open label
  • rectal cancer
  • smoking cessation